{
  "slug": "black-seed-oil",
  "name": "Black Seed Oil (Nigella sativa)",
  "alternate_names": [
    "Nigella sativa oil",
    "Black cumin seed oil",
    "Thymoquinone (TQ)",
    "Kalonji oil"
  ],
  "mechanism": [
    "NF-kB pathway inhibition",
    "NRF2/ARE antioxidant-response activation",
    "AMPK metabolic-signaling activation",
    "NLRP3 inflammasome modulation"
  ],
  "target": [
    "NF-kB / inflammatory cytokine cascade",
    "NRF2 / ARE antioxidant axis",
    "AMPK metabolic signaling",
    "Plasma lipid pool (TC / LDL-C / TG)",
    "Glycemic indices (FBG / HbA1c)"
  ],
  "use_case": [
    "plasma-lipid profile (TC/LDL/TG · research-context meta-analysis)",
    "glycemic indices in dysglycemic populations (research-context meta-analysis)",
    "blood-pressure (modest changes · research-context meta-analysis)",
    "inflammatory-marker modulation (research-context)",
    "allergic-symptom / respiratory subjective score (small-RCT research-context)"
  ],
  "body_system": [
    "CARDIO",
    "METABOLISM",
    "IMMUNE",
    "RESP",
    "LIVER"
  ],
  "evidence_tier": "B",
  "evidence_anchor_pmid_count": 3,
  "dosage_range": "Research trials and meta-analyses most commonly used black seed (Nigella sativa) seed oil 1-3 g/day, or seed powder 1-2 g/day, over 8-12 weeks; thymoquinone is the principal active constituent. Educational reference describing the doses studied — not a dosing recommendation.",
  "safety_notes": "Generally well tolerated at studied doses; mild GI discomfort most common. Thymoquinone may potentiate antidiabetic and anticoagulant/antiplatelet drugs — consult a clinician if on these. High doses not advisable (animal liver/kidney toxicity at extremes). Inadequate pregnancy/lactation data. Educational, not medical advice.",
  "regulatory": {
    "fda": "Dietary supplement under DSHEA; Nigella sativa has a history of food use, no independent GRAS Notice (GRN); structure/function claims only",
    "efsa": "0 authorized / 0 non-authorized health claims (no claim dossier submitted); food-use history but no EFSA claim evaluation — no health claim may be made cross-border in the EU",
    "anvisa": "Vegetable-oil category subject to case-by-case ANVISA assessment (RDC 243/2018 framework); no standalone authorized functional (alegacao funcional) claim"
  },
  "authorized_claims": [],
  "ingredient_hub_url": "https://asxan.ai/ingredients/black-seed-oil/",
  "related_goal_slugs": [
    "heart-health",
    "inflammation-relief"
  ],
  "related_lifestyle_slugs": [
    "senior-60-plus"
  ],
  "last_evidence_review": "2026-06-13",
  "schema_version": "nc-public-v0.2",
  "api_version": "nc-public-v0.3",
  "_meta": {
    "last_evidence_review": "2026-06-13",
    "ip_axes_disclosed": {
      "public_axes": [
        "mechanism",
        "target",
        "use_case",
        "body_system",
        "evidence_tier",
        "dosage_range",
        "safety_notes",
        "regulatory",
        "authorized_claims"
      ],
      "ip_axes_not_exposed": [
        "proprietary_formula_ratios",
        "clinical_protocol_internals",
        "rnd_pipeline_compounds",
        "supplier_specific_grade_specifications",
        "unpublished_endpoint_data"
      ],
      "rationale": "asxan.ai surfaces the educational, evidence-tier-disclosed slice. Formula composition, clinical-protocol internals, and RnD pipeline data are intentionally outside this public surface."
    }
  }
}